Preoperative radiation improved T-cell infiltration in patients with HR+ HER2- breast cancer when administered in combination ...
Presented at 2025 SABCS, the phase III lidERA trial showed that oral SERD giredestrant reduced the risk of invasive disease ...
One in four patients with HR+ HER2- metastatic breast cancer remained progression free for at least four years with Kisqali ...
The results from HER2CLIMB-05 study, presented at the 2025 SABCS annual meeting, demonstrated that tucatinib (TUKYSA) added ...
Arcellx’s Phase 2 iMMagine 1 trial of anito cel in heavily pretreated multiple myeloma delivered a 96% response rate, 74% ...
New clinical data presented at the 67th ASH Annual Meeting indicated that Lunsumio could be a strong candidate for earlier ...
Early Phase 1b data for enozertinib, presented at the ESMO Asia Congress 2025, show strong systemic and intracranial activity ...
Harvard scientists have defined the exact DNA cross-link created by colibactin, a gut microbial toxin associated with ...
Scientists have demonstrated an automated bioreactor system that produces large numbers of human lung organoids. The ...
Researchers have developed intranasal spherical nucleic acids that activate the cGAS–STING pathway and reprogram the ...
Durvalumab (Imfinzi) combined with FLOT chemotherapy has been approved by the FDA as the first perioperative immunotherapy for resectable gastric and GEJ adenocarcinoma. The Phase III MATTERHORN trial ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback